The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Azacitidine, venetoclax & magrolimab in patients with newly diagnosed & R/R high-risk AML
Sankalp Arora, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the results of a Phase Ib/II clinical trial evaluating the combination of azacitidine, venetoclax, and magrolimab in patients with newly diagnosed and relapsed/refractory (R/R) high-risk acute myeloid leukemia (AML). Dr Arora highlights the encouraging response rates observed, with a composite complete response of approximately 90% in TP53 wild-type patients and 49% in TP53-mutated patients, but notes that survival outcomes were disappointing, with a median overall survival (OS) of around 10 months for the entire cohort. Dr Arora then goes on to summarize data from single-cell sequencing of the TP53-mutated samples. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
